Yeast on the Final Frontier
A team led by Imperial College London has launched a miniature lab into Earth orbit to test the production of edible proteins in space with the help of yeast-based biotech.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 241 entries already.
Entries by Uta Mommert
Whey Waste Finds New Life as Protein
French dairy heavyweight Bel Group has teamed up with Standing Ovation in a bid to transform surplus whey from cheese production into high-value casein proteins using precision fermentation. The collaboration is set to address the longstanding issue of under-utilised acid whey, a by-product that often goes to waste in the dairy sector.
Netherlands Sets Sights on Global Biotech Leadership
The Netherlands has set itself an ambitious goal: to be among the global leaders in biotechnology by 2040. This vision is backed by an initial commitment of €1.3 billion in funding.
Gene therapy manufacturing: Fuse Vectors secures US$5.2m
Fuse Vectors has secured US$5.2m in pre-seed financing to revolutionise gene therapy manufacturing with its cell-free viral vector technology. The Danish company is aiming to make treatments more accessible and cost-effective by streamlining production.
Aplagon secures €7m for APAC development
Helsinki-based Aplagon has secured €7m in financing to advance its therapeutic APAC into Phase 2a clinical trials.
Green Biotech Fund surges past €150M target
Dutch venture capital firm Forbion revealed that its BioEconomy Fund I has amassed €164.5m. This surpasses the fund’s initial target of €150m, highlighting the increasing interest from investors in the commercial viability of biotech solutions that tackle worldwide sustainability issues.
FDA greenlights expanded use of Ozempic
The FDA has approved Novo Nordisk’s blockbuster drug Ozempic (semaglutide) for patients with chronic kidney disease who also have type 2 diabetes.
BIOTECH SUMMIT AUSTRIA: Seed to succeed
The BIOTECH SUMMIT AUSTRIA 2024 in Innsbruck brought together leaders, innovators and investors to network, interact and to enjoy being part of the booming Austrian biotech community. It showcased science, funding and collaboration opportunities, setting the stage for 2025 in Graz.
Novo Nordisk signs deal for monthly GLP-1 agonist
Novo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.
Purespring bags £80m to transform kidney disease treatment
Purespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.